OPCH
Get informed when a big investor buys or sells
+ FollowUndervalued by 227.9% based on the discounted cash flow analysis.
| Market cap | $3.28 Billion |
|---|---|
| Enterprise Value | $3.10 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.28 |
| Beta | 0.68 |
| Outstanding Shares | 156,653,000 |
| P/E Ratio | 15.86 |
|---|---|
| PEG | -529.78 |
| Price to Sales | 0.57 |
| Price to Book Ratio | 2.57 |
| Enterprise Value to Revenue | 0.55 |
| Enterprise Value to EBIT | 8.77 |
| Enterprise Value to Net Income | 15 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0652▼ 48.01% |
|---|---|
| Total Calls | 1,275,200▲ 13.05% |
| Total Puts | 83,200▼ 86.48% |
Holdings and activity of institutional investors.
| Ownership % | 104.40%▲ 4.17% |
|---|---|
| Total Invested | $4.46B▼ 14.64% |
| Investors Holding | 3780% |
No data
Controls taxation, trade, and entitlement spending, crucially influencing corporate tax policy and Medicare pricing, which are vital for a pharmacy business.
Allocates discretionary federal spending, directly determining funding levels for federal healthcare programs (e.g., Medicare/Medicaid) which are major revenue sources for pharmacies.
Directly regulates the FDA, impacting drug approvals and safety, and oversees labor laws critical for a company employing a large workforce.